3 active not recruiting, 3 completed, 2 recruiting, 1 terminated. 5 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Completed 2, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Not applicable | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow HER2-Positive Breast Carcinoma: new trials by email Literature Review of HER2-Positive Breast Carcinoma trials Research Report on HER2-Positive Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer Biospecimen Collection, Electronic Health Record Review, Survey Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Withdrawn | City of Hope Medical Center | 2026-05-12 | 2026-06-25 | |
| Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk Non-Interventional Study - HER2-Positive Breast Carcinoma | Recruiting | Mayo Clinic | 81 | 2023-11-16 | 2026-09-02 | |
| Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial Chemotherapy, Computed Tomography, Fludeoxyglucose F-18 - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 235 | 2023-05-10 | 2026-10-19 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Copanlisib, Pertuzumab, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2021-05-20 | 2025-10-01 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-04-26 | 2026-08-19 |
| Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer Biospecimen Collection - Breast Adenocarcinoma, HER2-Positive Breast Carcinoma | Recruiting | Mayo Clinic | 230 | 2020-07-31 | 2026-06-16 | |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer Anastrozole, Denifanstat, Exemestane - Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma | Phase 2 | Completed | Mayo Clinic | 17 | 2017-08-03 | 2026-10-09 |
| Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure - HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 315 | 2014-02-18 | 2026-10-06 |
| Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery - HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 143 | 2012-12-06 | 2023-10-17 |
Breast Neoplasms (5) · Neoplasm Metastasis (2) · Stomach Neoplasms (2) · Brain Neoplasms (1) · Carcinosarcoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Salivary Gland Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Breast Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Neoplastic Processes (2)
Specimen Handling (5) · Magnetic Resonance Spectroscopy (4) · Biopsy (3) · CT-P6 (3) · Ogivri (3) · Ontruzant (3) · PF-05280014 (3) · Trastuzumab (3) · trastuzumab biosimilar HLX02 (3) · 2C4 antibody (2) · pertuzumab (2) · Anastrozole (1) · Aromatase Inhibitors (1) · Carboplatin (1) · Disulfides (1)
National Cancer Institute (NCI) (5) · Mayo Clinic (3) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1)
United States (10) · Puerto Rico (2) · Canada (1) · South Korea (1)
A P Chen (1) · Heather Jacene (1) · In A Kim (1) · Jose G Bazan (1) · Kalpana Muthusamy, MBBS, MD (1) · Kanwal P Raghav (1) · Mothaffar F Rimawi (1) · Saranya Chumsri, MD (1) · Senthilkumar Damodaran (1) · Tufia C. Haddad, M.D. (1)
U10CA180868 (2), UM1CA186688 (2), P30CA033572 (1), U10CA012027 (1), U10CA021661 (1), U10CA180820 (1)